Ocular Therapeutix
Latest round
- Series D
Last raised
- May 2013
Total raised
- $67M
Investors
- 6
About Ocular Therapeutix
Founded in 2006 and based in Massachusetts, US, Ocular Therapeutix Inc. operates as a provider of ophthalmic therapeutic products for ophthalmology and ophthalmic surgery applications., before deducting placement agent fees and other offering expenses. As of 2024, the company is headed by its CEO Pravin U. Dugel. The company bears the ticker symbol NASDAQ: OCUL. Ocular Therapeutix’s product portfolio includes sustained-release therapies designed to enhance patient compliance and treatment outcomes. Key products include DEXTENZA® and ReSure® Sealant, which are used for managing post-surgical inflammation and sealing incisions, respectively. The company is also developing new therapies using its ELUTYX™ technology, which allows for sustained drug release and has the potential to transform treatments for retinal diseases, glaucoma, and other ophthalmic conditions.
Who invested in Ocular Therapeutix
6 investors across 6 rounds
See all investors in Ocular Therapeutix
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Ocular Therapeutix
Who invested in Ocular Therapeutix?
Ocular Therapeutix has 6 investors on record across 6 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Ocular Therapeutix raised?
Ocular Therapeutix has raised 6 venture rounds. Sign up free to see how much each round raised and the total.
When did Ocular Therapeutix last raise money?
Ocular Therapeutix's most recent round on record is a Series D, in May 2013.
What does Ocular Therapeutix do?
Founded in 2006 and based in Massachusetts, US, Ocular Therapeutix Inc.
Where is Ocular Therapeutix headquartered?
Ocular Therapeutix is headquartered in Bedford, US.
Which VCs invest in companies like Ocular Therapeutix?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Ocular Therapeutix's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series D
Raising like Ocular Therapeutix? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.